The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis

Blood

Volumn 126, Issue 11, 2015, Pages 1379-1389

  Nickel, Katrin F ^a,b,c   Ronquist, Göran ^d   Langer, Florian ^a   Labberton, Linda ^b,c   Fuchs, Tobias A ^a   Bokemeyer, Carsten ^a   Sauter, Guido ^a   Graefen, Markus ^a   Mackman, Nigel ^e   Stavrou, Evi X ^f,g   Ronquist, Gunnar ^d   Renné, Thomas ^a,b,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; FIBRIN; HIGH MOLECULAR WEIGHT KININOGEN; PLASMA KALLIKREIN; POLYPHOSPHATE; RECOMBINANT ANTIBODY; THROMBIN; BLOOD CLOTTING FACTOR 12A; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; CELL SURFACE; CONTROLLED STUDY; EXOSOME; HUMAN; HUMAN CELL; LUNG EMBOLISM; MALE; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROSTASOME; PROSTATE CANCER; PROSTATE CANCER CELL LINE; THROMBOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; METABOLISM; PROSTATE TUMOR; PULMONARY EMBOLISM; SECRETORY VESICLE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; FACTOR XII; FACTOR XIIA; FIBRIN; HUMANS; MALE; MICE; POLYPHOSPHATES; PROSTATIC NEOPLASMS; PULMONARY EMBOLISM; SECRETORY VESICLES; THROMBIN; THROMBOSIS;

EID: 84942466626     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-622811     Document Type: Article

References (76)

1. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49(6):1404-1413.
2. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160(6):761-768.
3. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634.
4. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712-1723.
5. Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013;122(14):2310-2317.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
7. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275.
8. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687-1693.
9. Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C. In vivo roles of factor XII. Blood. 2012;120(22):4296-4303.
10. von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819-835.
11. Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271-281.
12. Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost. 2011;105(2):269-273.
13. Matafonov A, Leung PY, Gailani AE, et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood. 2014;123(11):1739-1746.
14. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA. 2006;103(4):903-908.
15. Müller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139(6):1143-1156.
16. Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood. 2012;119(25):5972-5979.
17. Babiker AA, Hamad OA, Sanchez J, Ronquist G, Nilsson B, Ekdahl KN. Prothrombotic effect of prostasomes of metastatic cell and seminal origin. Prostate. 2007;67(4):378-388.
18. Langer F, Chun FK, Amirkhosravi A, et al. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers. Thromb Haemost. 2007;97(3):464-470.
19. Ronquist G. Prostasomes are mediators of intercellular communication: from basic research to clinical implications. J Intern Med. 2012;271(4):400-413.
20. Arvidson G, Ronquist G, Wikander G, Ojteg AC. Human prostasome membranes exhibit very high cholesterol/phospholipid ratios yielding high molecular ordering. Biochim Biophys Acta. 1989;984(2):167-173.
21. Henderson MC, Azorsa DO. The genomic and proteomic content of cancer cell-derived exosomes. Front Oncol. 2012;2:38.
22. Waldenström A, Ronquist G. Role of exosomes in myocardial remodeling. Circ Res. 2014;114(2):315-324.
23. Weiss EJ, Hamilton JR, Lease KE, Coughlin SR. Protection against thrombosis in mice lacking PAR3. Blood. 2002;100(9):3240-3244.
24. Larsson M, Rayzman V, Nolte MW, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med. 2014;6(222):222ra17.
25. Haubold K, Rink M, Spath B, et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost. 2009;101(6):1147-1155.
26. Kravtsov DV, Matafonov A, Tucker EI, et al. Factor XI contributes to thrombin generation in the absence of factor XII. Blood. 2009;114(2):452-458.
27. Smith SA, Morrissey JH. Sensitive fluorescence detection of polyphosphate in polyacrylamide gels using 4′,6-diamidino-2-phenylindol. Electrophoresis. 2007;28(19):3461-3465.
28. Saito K, Ohtomo R, Kuga-Uetake Y, Aono T, Saito M. Direct labeling of polyphosphate at the ultrastructural level in Saccharomyces cerevisiae by using the affinity of the polyphosphate binding domain of Escherichia coli exopolyphosphatase. Appl Environ Microbiol. 2005;71(10):5692-5701.
29. Llorente A, de Marco MC, Alonso MA. Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line. J Cell Sci. 2004;117(Pt 22):5343-5351.
30. Wang R, Zhang T, Ma Z, et al. The interaction of coagulation factor XII and monocyte/macrophages mediating peritoneal metastasis of epithelial ovarian cancer. Gynecol Oncol. 2010;117(3):460-466.
31. Trousseau A. Phlegmasia alba dolens. In:Trousseau A, ed. Lectures on Clinical Medicine Delivered at the Hotel Dieu de Paris. London, United Kingdom: The New Sydenham Society; 1872:281-295.
32. Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122(11):1873-1880.
33. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012;119(4):924-932.
34. Dvorak HF, Van DeWater L, Bitzer AM, et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res. 1983;43(9):4434-4442.
35. Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med. 2009;206(9):1913-1927.
36. Tesselaar MET, Romijn FPHTM, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007;5(3):520-527.
37. Thaler J, Ay C, Weinstabl H, et al. Circulating procoagulant microparticles in cancer patients. Ann Hematol. 2011;90(4):447-453.
38. Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009;15(22):6830-6840.
39. Tavoosidana G, Ronquist G, Darmanis S, et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci USA. 2011;108(21):8809-8814.
40. Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res. 2010;125(6):511-512.
41. Auwerda JJ, Yuana Y, Osanto S, et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2011;105(1):14-20.
42. Thaler J, Ay C, Mackman N, et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost. 2012;10(7):1363-1370.
43. Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost. 2009;7(8):1421-1423.
44. Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renné T, ten Cate H, Spronk HM. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost. 2012;10(7):1355-1362.
45. Johne J, Blume C, Benz PM, et al. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol Chem. 2006;387(2):173-178.
46. Walsh PN, Griffin JH. Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood. 1981;57(1):106-118.
47. Castaldi PA, Larrieu MJ, Caen J. Availability of platelet Factor 3 and activation of factor XII in thrombasthenia. Nature. 1965;207(995):422-424.
48. Roeise O, Sivertsen S, Ruud TE, Bouma BN, Stadaas JO, Aasen AO. Studies on components of the contact phase system in patients with advanced gastrointestinal cancer. Cancer. 1990;65(6):1355-1359.
49. Battistelli S, Stefanoni M, Lorenzi B, et al. Coagulation factor levels in non-metastatic colorectal cancer patients. Int J Biol Markers. 2008;23(1):36-41.
50. Pan J, Qian Y, Weiser P, et al. Glycosaminoglycans and activated contact system in cancer patient plasmas. Prog Mol Biol Transl Sci. 2010;93:473-495.
51. Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood. 2010;116(20):4353-4359.
52. Nickel KF, Spronk HM, Mutch NJ, Renné T. Time-dependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. Blood. 2013;122(23):3847-3849.
53. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005;57(1):27-77.
54. Smith SA, Choi SH, Collins JN, Travers RJ, Cooley BC, Morrissey JH. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood. 2012;120(26):5103-5110.
55. Alvarenga PH, Xu X, Oliveira F, et al. Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate. Arterioscler Thromb Vasc Biol. 2013;33(12):2759-2770.
56. Stavrou EX, Fang C, Merkulova A, et al. Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood. 2015;125(4):710-719.
57. Jain S, Pitoc GA, Holl EK, et al. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci USA. 2012;109(32):12938-12943.
58. Steiner S, Plehn G, Reinecke P, et al. Disseminated microvascular pulmonary tumor cell embolism: a rare cause of fulminant pulmonary hypertension. Onkologie. 2004;27(6):566-568.
59. Pinckard JK, Wick MR. Tumor-related thrombotic pulmonary microangiopathy: review of pathologic findings and pathophysiologic mechanisms. Ann Diagn Pathol. 2000;4(3):154-157.
60. Sancho-Chust JN, Ferreres J, Pineda J, et al. Pulmonary tumor embolism as an initial manifestation of pancreatic adenocarcinoma. Respir Care. 2009;54(12):1732-1735.
61. Bernstein KE, Esther CR Jr. The functional role of angiotensin-converting enzyme as explored by using knockout mice. Adv Nephrol Necker Hosp. 1998;28:213-223.
62. Oschatz C, Maas C, Lecher B, et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity. 2011;34(2):258-268.
63. Sala-Cunill A, Bjorkqvist J, Senter R, et al. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol. 2014;135(4)1031-1043.
64. Blais PA, Côté J, Morin J, et al. Hypotensive effects of hemopressin and bradykinin in rabbits, rats and mice. A comparative study. Peptides. 2005;26(8):1317-1322.
65. Kuijpers MJ, van der Meijden PE, Feijge MA, et al. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol. 2014;34(8):1674-1680.
66. Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010;116(19):3981-3989.
67. Lyman GH, Khorana AA, Kuderer NM, et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189-2204.
68. Lee AY, Levine MN, Baker RI, et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.
69. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18(17):3078-3083.
70. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 2000;84(5):805-810.
71. Wharin C, Tagalakis V. Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. Blood Rev. 2014;28(1):1-8.
72. Mayforth RD, Quintáns J. Designer and catalytic antibodies. N Engl J Med. 1990;323(3):173-178.
73. Chyung Y, Vince B, Iarrobino R, et al. A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. 2014;113(4):460-6.e2.
74. Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood. 2011;118(19):5302-5311.
75. Yau JW, Liao P, Fredenburgh JC, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood. 2014;123(13):2102-2107.
76. Büller HR, Bethune C, Bhanot S, et al; FXI-ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232-240.